4:15 PM ET
8-K
Investor Presentation
Rezolute Investor Presentation
Rezolute, Inc. released an updated corporate investor presentation on October 29, 2026, highlighting its late-stage clinical programs for ersodetug in treating refractory hypoglycemia. The company reported a cash position of $108 million, providing a projected operational runway through the first quarter of 2028.